- Breast cancer that is clinical stage T1-4, N0-3 disease at presentation and HER2-positive
|
-
Received neoadjuvant chemotherapy with one of the following regimens: docetaxel/trastuzumab/pertuzumab (THP), paclitaxel/methotrexate/cisplatin (TMP), doxorubicin/cyclophosphamide/paclitaxel/trastuzumab/pertuzumab (AC-TH(P))
|
- docetaxel/carboplatin/trastuzumab/pertuzumab (TCH(P))
|
- fluorouracil/doxorubicin/cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FAC-TH(P)), or fluorouracil/epirubicin/cyclophosphamide-docetaxel/trastuzumab/pertuzumab (FEC-TH(P)). Note: apart from TCHP, where T is docetaxel, treatment with docetaxel or paclitaxel is acceptable
|
-
Adequate excision: surgical removal of all clinically evident disease in the breast and lymph nodes
|
-
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
|